Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 13;15(11):1113-1117.
doi: 10.7150/ijms.25687. eCollection 2018.

Urinary Orosomucoid A Potential Marker Of Inflammation In Psoriasis

Affiliations

Urinary Orosomucoid A Potential Marker Of Inflammation In Psoriasis

Péter Kustán et al. Int J Med Sci. .

Abstract

Background: Psoriasis is one of the most common chronic, life-long dermatologic diseases, which has considerable negative effects on quality of life. Psoriasis is considered as a systemic inflammatory disease, thus acute phase proteins such as C-reactive protein (CRP) and orosomucoid (ORM) have been shown to play a role in its pathophysiology. This study was aimed to compare CRP, serum ORM (se-ORM) and urinary ORM (u-ORM) levels of psoriatic patients to healthy individuals. Methods: 87 psoriatic patients and 41 healthy individuals were enrolled. Simultaneously obtained venous blood and spot urine samples were analysed. High sensitivity CRP and se-ORM levels were determined by routine procedures on automated analyzers. Urinary ORM was measured by a novel automated turbidimetric assay. U-ORM was referred to urinary creatinine (u-ORM/u-CREAT, mg/mmol). Results: Significantly higher hsCRP (p<0.001) and u-ORM/u-CREAT (p=0.001) levels were found among psoriatic patients compared to controls. No significant differences were found between the groups regarding se-ORM levels. HsCRP, se-ORM and u-ORM/u-CREAT levels were significantly higher in patients with severe psoriasis than in mild and moderate cases (p<0.05). Conclusion: As a highly sensitive, easily available biomarker u-ORM shows itself capable of becoming a new inflammatory marker in psoriasis providing clinically useful information on disease severity.

Keywords: Orosomucoid; Psoriasis; Urine, Biomarker, Inflammation.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
U-ORM/u-CREAT levels in psoriatic patients. A: u-ORM/u-CREAT levels in psoriasis compared to healthy controls. B: u-ORM/u-CREAT levels based on Psoriasis Area and Severity Index (PASI), mild: PASI<7, moderate: PASI:7-12, severe: PASI>12. C: u-ORM/u-CREAT levels in psoriatic arthritis, n.s.: not significant (p=0.23)

References

    1. Parisi R, Symmons DP, Griffiths CE. et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. The Journal of investigative dermatology. 2013;133:377–85. - PubMed
    1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71. - PubMed
    1. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology. 1999;41:401–7. - PubMed
    1. Smith CH, Barker JN. Psoriasis and its management. Bmj. 2006;333:380–4. - PMC - PubMed
    1. Shahwan KT, Kimball AB. Psoriasis and Cardiovascular Disease. The Medical clinics of North America. 2015;99:1227–42. - PubMed